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1. Introduction  
Since they introduction in the treatment of erectile dysfunction (ED), phosphodiesterase 
type 5 (PDE-5) inhibitors have achieved widespread acceptance. Today PDE-5 inhibitors are 
considered as first-line oral pharmacotherapy in the management of ED (Hatzimouratidis et 
al., 2010). However, penile implants are still a popular choice, especially in patients who 
have failed to achieve erections by chemical enhancement, who prefer a permanent solution 
to their condition or in those who have considerable scar tissue in the penis resulting in 
erection deformalities (Mulcahy 1999). Despite its invasiveness, penile prostheses provide 
high satisfaction rates  (Montague & Angermeier 2001). 
The types of prosthesis most commonly implanted are the two-piece and the three-piece 
inflatable device, and the soft and malleable prosthesis. In the last few years the three-
piece inflatable device has been used for preference, as it improves the erection with the 
most acceptable functional and cosmetical results (Minervini et al., 2006; Bettocchi et al., 
2008). 
Engineering changes and designs revisions have reduced the mechanical malfunctions 
associated with inflatable penis prostheses to less than 5 % (Carson et al., 2000; Carson 2004). 
As penile prostheses are now expected to function for an average of 8-12 years post 
implantation, infection has become a more significant problem. The incidence of infection 
has been reported to range from 0.5 to 17.7% (Quesada & Light, 1993; Wilson & Delk, 1995) 
usually about 1-3 % in case of primary implantation, and about 10-13 % in case of revision or 
reimplantation (Abouassaly et al., 2004).  
The traditional treatment of penile prosthesis infection is systematic and local antibiotics 
application with the complete removal of the device followed by reinsertion within 2–12 
months. However, removal of the device can lead to corporeal fibrosis, making dilation of 
the corporeal bodies difficult and reinsertion of a new device more complicated (Brant et al., 
1996; Mulcahy, 1999). 
To reduce the risk of device associated infections and to avoid the difficulties associated 
with late reinsertions many modifications have been developed such as antibiotic or 
hydrophilic coated devices and immediate replacement of the infected prosthesis (salvage 
techniques). 
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The aim of this chapter is to summarize the different methods of prevention and treatment 
of penile prosthesis infections. 
2. Pathogenesis/epidemiology  
Staphylococcus species, especially Staphylococcus epidermidis are the most common infecting 
pathogens, isolated from 35 to 56% of infected penile prostheses patients (Carson , 2003). 
Gram-negative enteric bacteria including Proteus mirabilis, Pseudomonas aeruginosa, 
Escherichia coli and Serratia marcenses may also be pathogens, accounting for 20 % of 
infections (Abouassaly et al., 2004). Gram-negative bacteria can combine with anaerobic 
organisms in severe infections, such as Bacteroides species, and lead to gangrene of the penis. 
Fungi, mycobacteria and Neisseria gonorrhea have also been reported as etiological agents in 
penile prosthesis infections (Carson, 1989; Abouassaly et al., 2004). 
Penile prostheses get infected predominantly secondary to bacterial seeding at the time of 
surgery. Prosthetic materials attract bacteria and support subsequent biofilm formation. In a 
multicenter study culture positive bacteria were found in 70% of patients with clinically 
uninfected penile prostheses during revision surgery for mechanical malfunction. 
Saphylococcus species were cultured in 90 % of the cases (Henry et al., 2004), which have an 
enhanced ability to produce glycocalyx biofilm. 
Penile prosthesis infections can be divided into clinically apparent and subclinical infections. 
Clinical infections present with, penile pain, induration, erythema, fever, purulent drainage 
from the wound and extrusion. Subclinical infections most often manifest by chronic 
prosthesis-associated pain. 
3. Risk factors  
Known risk factors for penile prosthesis infection include urinary tract infection, 
infections elsewhere in the body and hematogenous spread (Carson & Robertson, 1988; 
Little & Rhodus, 1992). There is an increased incidence of infection among patients 
undergoing primary implantation with penile reconstruction or secondary prosthesis 
revision compared to primary implantation alone, probably due to the increased duration 
of surgery (Quesada & Light, 1993; Jarow, 1996). The role of diabetes mellitus and spinal 
chord injury, as risk factors of penile prosthesis infection are contradictory (Jarow, 1996; 
Cakan et al., 2003). 
4. Prevention  
4.1 General aspects 
Because in most cases bacterial contamination occurs at the time of surgery, it is essential to 
use appropriate preoperative preparations. Short preoperative hospital stays have been 
documented to maintain low virulence (Carson, 2003). It is important to eliminate skin 
infections and to have sterile urine prior to surgery. Washing the genital region with strong 
soap in the days before the procedure, preoperative shaving and an aggressive scrub of the 
operating area is recommended to decrease the risk of infection (Mulcahy, 1999; Gomelsky 
& Dmochowski, 2003). 
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During surgery adequate sterile technique, short operating time, minimal tissue 
devitalization along with effective wound closure can all decrease the rate of perioperative 
infections (Scott, 1987). 
4.2 Perioperative antibiotic prophylaxis 
Athough the effectiveness of prophylactic perioperative antibiotics for implantation of 
penile prosthesis has never been proven by prospective studies, their use has become 
established and favored by most urologists. Antibiotics should be administered 1-2 hours 
prior to surgery and continued for 36-48 hours postoperative. Most common pathogenic 
organisms most likely to produce infections must be targeted when choosing prophylactic 
antibiotics. Therefore traditional prophylaxis include a parenteral aminoglycoside for Gram-
negative and a first- or second generation cephalosporin or vancomycin for Gram-positive 
organisms coverage (Schwartz et al., 1996; Naber et al., 2001). Schwarz et al found in a 
randomized prospective trial of 20 patients that oral fluoroquinolone (ofloxacin) 
administered 2 hours before surgery achieved significantly higher intracavernosal levels 
and was more cost-effective than the combination of gentamicin and cefazolin (Schwartz et 
al., 1996). To estimate the safety and efficacy of this prophylaxis modality, further studies 
with similar settings, but bigger sample size should be performed. 
4.3 Antibiotic impregnation 
Early efforts in device impregnation focused on coating catheters with antibiotics. In 1995 
Raad et al reported that in in vitro studies catheters coated with a combination of rifampin 
and minocycline provided significantly better inhibitory activities against S. epidermidis, S. 
aureus and E. faecalis than catheters coated with either drug alone or vancomycin (Raad et 
al., 1995). After additional in vitro and in vivo studies in 2001 the US Food and Drug 
Administration approved the use of penile prosthesis coated with a combination of 
rifampin and minocycline called InhibiZone. The concentrations of the antibiotics, while 
adequate for decreasing colonization, provided only minimal serum levels of the agents. 
Coated inflatable penile prostheses are implanted in a fashion similar to those without 
antibiotic treatment except that the devices are not soaked prior to implantation (Carson, 
2004). 
In a retrospective study Carson et al reported 61,7% decrease in perioperative infection with 
InhibiZone compared to controls at 1 year post infection (Carson, 2004). The same group 
recently published their long-term clinical outcomes of almost 40,000 implants. There were 
significantly less revisions due to infections in the impregnated compared to the non-
impregnated group at up to 7.7 years of follow-up (1.1% vs 2.5%, respectively)(Carson et al., 
2011). In a subset of diabetic patients in the same series, the rate of infection-related 
revisions was significantly lower in the impregnated group compared to the controls at 7 
years (1,62 % vs 4,24 %)(Mulcahy & Carson, 2011). 
In 2007 Wilson et al. began a prospective randomized study comparing the infection rate of 
rifampin and minocycline coated implants with implants without impregnation (Wilson et 
al., 2007). After it became evident that the infection rate was less with the impregnated 
group they abandoned the other arm because of ethical considerations and compared they 
results with the previously published series of the same surgical team with noncoated 
implants (Wilson & Delk, 1995; Wilson et al. 1998). The use of antibiotic coated inflatable 
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penile prosthesis resulted in a statistically significant reduction in the infection rates 
compared with the historical data in nondiabetic virgin implant patients (p=0,0024), diabetic 
virgin implant patients (p=0,0141) and in revision patients in whom washout with antiseptic 
solutions was used (p= 0,0095). Revision without washout had the same infection rate (10%) 
as with noncoated implants.  
4.4 Hydrophilic coating 
In 2002 a hydrophilic penile prosthesis coating was developed which has been shown to 
decrease bacterial adherence in vitro and in animal models (Rajpurkar et al., 2004). This 
coating absorbs surgeon chosen intraoperative antibiotics that can elute into surrounding 
tissues over 24-72 h to further decrease infection (Hellstrom et al., 2003).  
Mansouri and colleagues compared the spectrum and durability, both in vitro and in vivo of 
the hydrophilic coated prosthesis dipped in vancomycin and the InhibiZone implants, and 
found that the antibiotic pre-impregnated prosthesis had a broader spectrum in vitro and a 
more durable antimicrobial activity in vitro and in an animal model than implants dipped in 
vancomycin (Mansouri et al. 2009). 
Clinical data on the hydrophilic coated inflatable penile prosthesis is limited. Wolter et al. 
presented their one-year experience with the device (Titan, Mentor Corporation, Santa 
Barbara, CA) (Wolter & Hellstrom 2004), the infection rate for 2357 coated penile prostheses 
was 1,06 % compared to 2,07 % in 482 uncoated penile prostheses implanted over the same 
time period. Although preliminary data using this device shows promise, long-term follow-
up and prospective studies are not yet available. 
5. Treatment  
Subclinical infections may be more common than clinically apparent infections. These 
infections are difficult to diagnose and even more challenging to treat. Parsons et al. 
recommend initial trial of oral antibiotic therapy using long-term antibiotics (ciprofloxacin 
500mg twice daily) (Parsons et al., 1993). Following initiation of antibiotics, pain suppression 
should suggest continuing antibiotics for 10–12 weeks. The authors reported a 60% success 
rate with conservative treatment of subclinical penile prosthesis infections. The use of oral 
cephalosporins (cefalexin and cephradine) has also been suggested for 10-12 weeks, 
although success rates are lower at 25-30% (Choong & Whitfield, 2000; Carson, 2003). If pain 
fails to resolve or rapidly returns after antibiotics, however, surgical intervention is 
appropriate. Parsons et al. have reported 90% success rate in treating these prostheses with 
an exchange protocol including systemic antibiotics for 24–48 h using vancomycin. The 
suspected infected prosthesis is then removed and a combination of vancomycin and 
protamine was used for antibiotic irrigation prior to reimplantation of a new prosthesis. 
Patients are maintained on vancomycin and parental antibiotics for 1 week (Parsons et al., 
1993; Carson, 2003). 
In case of clinically apparent infection surgical intervention along with antibiotics is of 
critical importance. The traditional treatment consists of the immediate removal of all the 
components followed by delayed reimplantation 2-12 months later (Gomelsky & 
Dmochowski, 2003; Mulcahy, 2003). The advantage of this solution is that the new implant 
is scheduled only when the infection has completely cleared. However, removal of the 
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device along with inflammation from the infectious process leads to corporeal fibrosis and 
scarring, which almost always results in penile shortening and may make dilation of the 
corporeal bodies very difficult, resulting reinsertion of a new device more complicated and 
sometimes impossible (Brant et al., 1996; Mulcahy, 1999). 
A salvage protocol was instituted in 1991 to avoid difficult reinsertion and maintain as 
much penile length as possible. The salvage procedure involves removing all parts of the 
infected prosthesis, washing the wound, and replacing the device at the same procedure. 
Mulcahy et al. recommend a sequence of irrigating solutions including kanamycin and 
bacitracin in normal saline followed by half-strength hydrogen peroxide, half-strength 
povidone-iodine solution, pressurized normal saline containing vancomycin and 
gentamicin, half-strength povidone-iodine, half-strength hydrogen peroxide, and finally 
another kanamycin/bacitracin solution (Mulcahy et al., 1995). Gloves, instruments, gowns, 
and drapes are changed and a new inflatable penile prosthesis is immediately implanted. 
Postoperatively, patients are treated with antibiotics (2x500 mg ciprofloxacin) for 4-6 weeks. 
Antibiotics can be modified based on culture and sensitivity results. The reported success 
rate of the salvage procedure is 84-91% (Brant et al., 1996; Mulcahy, 2003). To avoid 
complications of late reinsertion the salvage protocol is a treatment alternative of traditional 
delayed reimplantation, although in patients with life-threatening systemic conditions such 
as septicemia, or diabetic ketoacidosis, or in whom necrotizing infections with death of 
penile skin is occurring salvage procedure is not recommended (Brant et al., 1996; Mulcahy, 
1999).  
The delayed salvage procedure consists of placement of a drainage tube after removal of the 
prosthesis; antibiotic solution is irrigated through the drain and a new prosthesis is placed 
about 3 days later. However, Knoll et al could not find a statistically significant difference 
between immediate and delayed salvage procedure (Knoll, 1998), while there are the 
additional cost of the second surgical procedure. 
6. Further research  
Prospective studies and long-term follow up are needed to make stronger recommendations 
about the different methods in the prevention or treatment of penile prostheses infections, 
especially about the hydrophilic coated penile prosthesis. 
7. Conclusion 
The efforts to apply more effective methods of prevention and the new developments of 
prosthesis coatings resulted a significant reduction of the infectious complications of 
penile prosthesis implantation. Further improvements of surgical procedures and 
prosthesis materials and coatings can lead to further decrease of the infection rates in the 
future. 
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